ID :
145813
Tue, 10/12/2010 - 21:33
Auther :

BIOMALAYSIA 2010 TO SHOWCASE PROMINENT WORLD EXPERTS




KUALA LUMPUR, Oct 12 (Bernama) -- BioMalaysia 2010, the premier three-day
biotechnology event from Nov 1, will showcase prominent experts around the world
sharing the global impact on biotechnology.

It will also outline the vast potential the industry holds for Malaysian
entrepreneurs and the benefit biotechnology brings to the global community,
Malaysian Biotech Corporation (BiotechCorp) Chief Executive Officer
Iskandar Mizal Mahmood said Tuesday.

Themed "Innovating Commercialisation," BioMalaysia 2010 will feature nine
tracks on healthcare, agriculture and industrial biotechnology and is expected
to receive 10,000 visitors from 25 countries.

"It is also expected to attract 1,600 local and international conference
delegates and 61 very prominent subject matter expects," he said in a press
conference on BioMalaysia 2010 here.

The event is organised by the Ministry of Science, Technology and
Innovation, BiotechCorp and Protemp Exhibition Sdn Bhd, and supported by the
Malaysian Biotechnology Information Centre and Malaysian BioIndustry
Organisation.

Among distinguished speakers are Member of the Board of Novartis AG,
Switzerland, Alexandre F. Jetzer; NatureWorks' US Chief Operating Officer, Bill
Suehr; and Biocon Ltd General Manager S. Raman.

Iskandar said they would share the critical impact of biotechnology not
only in healthcare, agriculture and industrial development and the Malaysian
economy but also the difference a successful biotechnology industry could bring
to quality of life for all Malaysians.

Meanwhile, the BioMalaysia Exhibition will feature more than 300 local and
international exhibitors including from Korea, France and the Netherlands.

"Biotechnopreneurs should take advantage of this platform to network with
global experts and participants through the business partnering session,"
Iskandar said.

The conference and exhibition would help them keep abreast of the latest
developments and innovation in biotechnology, he added.

-- BERNAMA

X